Veriheal

DECEMBER 27, 2022

In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. . It’s excellent news, particularly since new research suggests psilocybin deserves further investigation.

Research and Development 102

Research and Development Therapy Consumption DEA 102

SpeedWeed

MAY 15, 2021

Doblin and his fellow researchers initially began exploring the therapeutic potential of MDMA back in the early 1980s, but these studies ground to a halt when the DEA banned ecstasy in 1985. MAPS is now enrolling participants for a further Phase 3 study that will allow another 50 subjects to access this promising new therapy.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

MAY 31, 2022

The only opportunity to currently participate would be through an active clinical trial or via an argument under the Right to Try Act of 2018 (an act which provides a pathway for patients with life-threatening diseases or conditions to access unapproved treatments). Emerging Non-Medical State-Regulated Path. Non-Commercial Operations.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

APRIL 21, 2022

Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . As we approach our anticipated FDA approval in 2023, the availability of cGMP-compliant MDMA will be secured for future therapeutic use. Berra Yazar-Klosinski, Ph.D.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

NOVEMBER 11, 2021

In fact, the United States Drug Enforcement Agency (DEA) issued a private letter ruling in September 2021 making clear that so long as Delta-8 has been extracted from a hemp plant (rather than a marijuana plant that contains.3% ” Under this timeline, New Yorkers can expect to see retail sales in approximately April of 2023.

Programs 52

Programs Hemp Supply Chain Seed-To-Sale 52

Cannabis Law Report

AUGUST 6, 2021

“We’re continuing to drive cost savings and operational efficiencies across the company, and remain broadly on track to our target of $150 – $200 million in fiscal 2022- fiscal 2023,” added Mike Lee , CFO. “We A replay will be accessible by webcast until 11:59 PM ET on November 4, 2021 at: [link]. Webcast Information.

Vaping 106

Vaping Research and Development Data Business 106

The Cannigma

MAY 15, 2023

While costs to access ketamine therapy can be high in some locations, and like any drug ketamine is not a cure-all, some patients and their doctors have been reporting life-changing results when no other treatment provided relief. The post How to access and assess ketamine therapy options appeared first on The Cannigma.

Therapy 106

Therapy Access Blood Pressure Treatment 106

Cannabis Law Report

JUNE 1, 2021

Implementation of supply chain optimization well underway with network optimization and complexity reduction initiatives expected to realize our previously stated cost savings of $150 million to $200 million by the end of the first half of FY 2023. A replay will be accessible by webcast until 11:59 PM ET on August 30, 2021 at: [link].

Data 96

Data Vaping Supply Chain Business 96

Canna Law Blog

JANUARY 8, 2025

cannabis community awaits the resumption of the DEA’s administrative law hearing on rescheduling marijuana later this month, this blog will take a glimpse at the ever-dynamic global landscape of cannabis policy. Phase I, implemented in 2023, legalized cannabis cultivation clubs, home cultivation, and personal possession.

Law 128

Law Programs Cultivation Hemp 128

Canna Law Blog

MARCH 21, 2022

Drug Enforcement Agency (DEA) reported that the federalization of hemp would result in hemp shielding criminal activities. Counties may also extend moratoriums, provided they submit an annual request with the ODA by January 1, 2023. These two counties have imposed local hemp moratoriums in accordance with SB 1564.

Hemp 98

Hemp DEA Conditions Agriculture 98

Canna Law Blog

JULY 14, 2023

On July 5, 2023, the FDA and FTC jointly announced six cease and desist letters to alleged delta-8 product makers. You can access the letters here. But, there’s a huge controversy about whether it can be controlled, with agencies like the DEA saying it is. You can read more about that issue here or here.

Packaging 98

Packaging Food Edibles THC 98

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10] DEA and the Controlled Substances Act. Under the Controlled Substances Act of 1970, DEA classifies drugs into one of five schedules.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Canna Law Blog

MAY 1, 2024

I take issue with some of the headlines , so here’s mine: “DEA Reportedly Agrees to Initiate Proposed Rulemaking to Reschedule Marijuana…”. HHS followed that directive, recommending on August 30, 2023, that marijuana be moved to Schedule III. I mentioned above that DEA “reportedly” has agreed to follow the HHS proposal.

DEA 111

DEA Marijuana Business Banking 111

Veriheal

NOVEMBER 7, 2024

The Drug Enforcement Administration (DEA) announced in August that a hearing regarding the reclassification decision will take place on December 2, 2024, before an administrative law judge. Then, the DEA will review the report and draft a final ruling, factoring in all relevant information submitted during the public comment period.

DEA 97

DEA Policy Chronic Pain Marijuana 97